Stoke Therapeutics
Open
$32.72
Prev. Close
$32.68
High
$32.72
Low
$32.66
Market Snapshot
$1.85B
-269.0
-1.67
$36.56M
170
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 170 full-time employees. The company went IPO on 2019-06-19. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The firm is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
emptyResult
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 170 full-time employees. The company went IPO on 2019-06-19. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The firm is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Recently from Cashu
Stoke Therapeutics: Leading RNA Innovations for Genetic Disorders and Treatment Advancements
Stoke Therapeutics: Pioneering RNA Medicine for Genetic Disorders Stoke Therapeutics, Inc., a biotechnology company based in Bedford, Massachusetts, is at the forefront of RNA medicine, focusing on re…
Stoke Therapeutics Innovates RNA Medicine with TANGO Technology for Genetic Disorder Treatments
Stoke Therapeutics Advances RNA Medicine with Innovative Technology Stoke Therapeutics, Inc., a biotechnology company based in Bedford, Massachusetts, focuses on pioneering RNA medicine to restore pro…
Stoke Therapeutics Advances Dravet Syndrome Treatment with Promising Zorevunersen Study Results
Revolutionizing Dravet Syndrome Treatment: Stoke Therapeutics' Promising Data on Zorevunersen Stoke Therapeutics, Inc., a pioneering biotechnology firm specializing in RNA medicine, presents groundbre…
Stoke Therapeutics Collaborates on GeneDx's New Pediatric Epilepsy Genetic Testing Access Program
GeneDx Launches Patient Access Program to Enhance Genetic Testing for Pediatric Epilepsy In a significant development within the biopharmaceutical industry, GeneDx, a leader in genomic insights, launc…